A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
A phase 3 trial of Rusfertide in myeloproliferative neoplasms, run by Protagonist Therapeutics, Inc., active and no longer recruiting.
Overview
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera is a phase 3 interventional study registered as NCT05210790 by Protagonist Therapeutics, Inc., with 293 participants enrolled, started 2022-04-01 and due to reach its primary completion in 2025-02-21. Interventions recorded: Placebo and Rusfertide.
Similar pages
not linked directly; found by shared links- TrialStudy to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
Shares Protagonist Therapeutics, Rusfertide, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialA Study of Rusfertide in Japanese Adults With Polycythemia Vera
Shares Rusfertide, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialStudy to Assess SLN124 in Patients With Polycythemia Vera
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialA Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialStudy of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialA Study of LY2784544 in Participants With Myeloproliferative Neoplasms
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialExtended Access of Momelotinib in Adults With Myelofibrosis
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialExtension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.